Does Eli Lilly's Future Depend on Acquisitions? (LLY)

Does Eli Lilly's Future Depend on Acquisitions?

Eli Lilly (NYSE: LLY ) faces declining revenues, as major drugs reach their patent expiration. In this video, health-care analyst David Williamson explains the challenges facing Eli Lilly, and what it can do to confront them. While it has a compelling pipeline, purchasing late-stage or already approved assets would strengthen Eli Lilly's near-term competitiveness. Certainly, there are pitfalls involved with an acquisition, and Eli Lilly's current licensing strategy mitigates some of that risk. Watch and find out if Eli Lilly needs to make a big move, or if staying the course is the better option.

Is Eli Lilly a buy or sell?
With two of its top three drugs poised to lose patent protection this year, is Eli Lilly a dividend stock headed nowhere fast? In a new premium report, The Motley Fool's senior pharmaceuticals analyst breaks down all of Lilly's moving parts, including an in-depth analysis of the company's must-know opportunities, and reasons to buy and sell today. To find out more, click here to claim your copy today.

Jeff Fischer and team have demystified options. And they can rack up income like $1,030... $2,626... and $3,228 on a schedule you can set your watch by!
That's why we're glad to announce every single one of their closely guarded strategies is available to YOU during May and June – 100% FREE, no strings attached! Just enter your email address in the box below...

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.

Report this Comment On March 22, 2013, at 1:46 AM, DannyHaszard wrote:

Eli Lilly did make $69 billion on Zyprexa (Olanzapine) and they still expect to capture 20% of the US market as well as a billion year on ZyprexaXR.
The patent only expires in the US and some Euro,Lilly announced they have an *authorized* distributor of generic Zyprexa.
I am keenly interested in how they resolve remaining Zyprexa litigation.
PTSD treatment for Veterans found ineffective.
Zyprexa can cause diabetes.
I took Zyprexa Olanzapine a powerful Lilly schizophrenic drug for 4 years it was prescribed to me off-label for post traumatic stress disorder was ineffective costly and gave me diabetes.
*FIVE at FIVE*
The Zyprexa antipsychotic drug,whose side effects can include weight gain and diabetes, was sold to Veterans,children in foster care, elderly in nursing homes.
*Viva Zyprexa* *five at five* was the Zyprexa sales rep slogan, meaning *5mg dispensed at 5pm would keep patients quiet*.
*Tell the truth don't be afraid*-- Daniel Haszard

updated Moments ago Sponsored by:
	DOW	15,387.58	52.30	0.34%
	S&P 500	1,669.16	2.87	0.17%
	NASD	3,502.12	5.69	0.16%

LLY	$55.14		+0.12	+0.22%
Eli Lilly & Co.		CAPS Rating:

GILD	$56.47		+0.73	+1.31%
Gilead Sciences		CAPS Rating:

BMY	$44.06		+0.30	+0.69%
Bristol-Myers Squi…		CAPS Rating:

AZN	$51.71		+0.21	+0.41%
AstraZeneca plc (A…		CAPS Rating:

0

Does Eli Lilly's Future Depend on Acquisitions?

Comments from our Foolish Readers

Report this Comment On March 22, 2013, at 1:46 AM, DannyHaszard wrote:

Add your comment.

Compare Brokers

Report This Comment

Sending report...

Today's Market

Create My Watchlist

You don't seem to be following any stocks yet!

Most Popular Articles

Related Tickers